Mentor v. American Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
Urology firms settle alleged infringement of Mentor's '211 trans-obturator patent, related to the firm's ObTape and AMS' Monarc subfascial hammocks for stress urinary incontinence in women. The deal includes a one-time payment by AMS of $2.5 mil. to Mentor and a non-exclusive cross-licensing agreement. Related lawsuits will be dismissed (1"The Gray Sheet" March 31, 2004, p. 13)...
You may also be interested in...
Litigation In Brief
J&J/Medtronic stent litigation: Supreme Court declines to review ruling awarding Johnson & Johnson/Cordis $271 mil. for infringement of stent patents, including those related to its Palmaz-Schatz('762), denying a writ of certiorari in the case. The U.S. Court of Appeals for the Federal Circuit had denied a rehearing in September 2003 after siding with J&J last August and remanded the case back to its original Wilmington, Del. district court (1"The Gray Sheet" Oct. 6, 2003, In Brief). Medtronic notes that the stents at issue are obsolete...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.